Business Context and Reporting Period
This Form 8-K filing by Tempest Therapeutics, Inc. (TPST) is dated August 17, 2026. The report addresses the reconvening of a special meeting of stockholders originally held on July 27, 2026, which was adjourned due to insufficient votes to approve a corporate governance proposal.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting matters rather than financial performance.
Material Changes and Corporate Actions
- Proposal Status: The Company failed to secure the required 75% affirmative vote to amend its Restated Certificate of Incorporation. The amendment sought to replace supermajority voting requirements and permit stockholder action by written consent.
- Voting Results: As of the July 27, 2026 meeting, 10,601,849 shares (71.6% of the 14,806,997 outstanding shares as of the May 28, 2026 record date) were present or represented by proxy, establishing a quorum. However, the vote count was insufficient to pass the proposal.
- Reconvened Meeting: The special meeting has been rescheduled for September 15, 2026, at 12:00 p.m. Eastern Time. The record date remains May 28, 2026, and previously submitted proxies will remain valid unless revoked.
Outlook, Risks, and Management Commentary
Management has engaged Sodali & Co., a proxy solicitation firm, to assist in obtaining adequate votes to achieve the required quorum and approval threshold for the reconvened meeting. The Company urges investors to review the definitive proxy statement filed with the SEC for detailed information regarding the proposal and the solicitation process. No changes have been made to the proposal text.
Key Facts for Investor Verification
- Verify the outcome of the reconvened special meeting scheduled for September 15, 2026.
- Review the definitive proxy statement filed on July 17, 2026, for details on the proposed Certificate of Amendment.
- Confirm whether the 75% supermajority voting threshold is successfully met in the upcoming vote.
- Check for any updates to the Company's 2025 Annual Report (Form 10-K) or subsequent 8-K filings regarding financial status, as this filing contains no financial data.